A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors.
Advanced Solid Tumor|Adult Solid Tumor|Adult Disease|Cancer|NSCLC
DRUG: TT125-802
Frequency and severity of adverse events (AEs) and serious adverse events (SAEs), Day 1 to approximately 16 weeks|Frequency of dose interruptions and dose reductions, Day 1 to approximately 16 weeks|Incidence of dose-limiting toxicities (DLTs), Day 1 to Day 21|Recommended Dose(s) for Expansion, Day 1 to Day 21
Plasma concentration of TT125-802 in blood, Day 1 to approximately 16 weeks|Objective response rate (ORR) assessed by RECIST v1.1, Day 1 to approximately 16 weeks|Duration of response (DOR) according to RECIST v1.1, Day 1 to approximately 16 weeks|Progression-free survival (PFS) according to RECIST v1.1, Day 1 to approximately 16 weeks
The purpose of this Phase 1, First-in-Human, Open-label Study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of TT125-802 as single agent in subjects with advanced solid tumors.